SALBUTAMOL ATTENUATES THE ARRHYTHMOGENIC EFFECT OF AMINOPHYLLINE IN CARDIAC ORGANOIDS EXPERIMENTAL MODEL

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F24%3A00137446" target="_blank" >RIV/00216224:14110/24:00137446 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.cksonline.cz/czech-cardiovascular-research-and-innovation-day-2024/sjezd.php?p=read_abstrakt_program&idabstrakta=70" target="_blank" >https://www.cksonline.cz/czech-cardiovascular-research-and-innovation-day-2024/sjezd.php?p=read_abstrakt_program&idabstrakta=70</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

SALBUTAMOL ATTENUATES THE ARRHYTHMOGENIC EFFECT OF AMINOPHYLLINE IN CARDIAC ORGANOIDS EXPERIMENTAL MODEL

Popis výsledku v původním jazyce

Background: The combination of aminophylline and salbutamol is used in the treatment of obstructive lung diseases. Side effects (including arrhythmias) of the individual bronchodilator drugs were described, those of combined treatment are almost unknown. We aimed to study the arrhythmogenic potential of combined aminophylline and salbutamol in vitro. Methods: We used the established model of atomic force microscopy (AFM) coupled with cardiac organoids from human pluripotent stem cells (hPSC-CMs). We focused on the chronotropic, inotropic, and arrhythmogenic effects of Salbutamol and Aminophylline alone and combined. Results: Salbutamol and Aminophylline had a synergistic chronotropic and inotropic effects compared to the effects of their separate application. Salbutamol reduced the arrhythmogenic effect of aminophylline, most likely mediated by endothelial nitric oxide synthase activated by beta-2 adrenergic receptors. Findings were replicated and confirmed using hPSC-CM derived from 2 cell lines (CCTL14 and CCTL12). Conclusions: Data suggest that salbutamol as an add-on therapy may not only deliver a bronchodilator effect but also increase the cardiovascular safety of aminophylline, as salbutamol reduces its arrhythmogenic potential. Acknowledgement CarDia (EXCELES, No. LX22NPO5104) EU Next Generation and by the EC Horizon Europe MUQUABIS GA no. 101070546. and MUNI/A/1624/2023 MEYS CR

Název v anglickém jazyce

SALBUTAMOL ATTENUATES THE ARRHYTHMOGENIC EFFECT OF AMINOPHYLLINE IN CARDIAC ORGANOIDS EXPERIMENTAL MODEL

Popis výsledku anglicky

Background: The combination of aminophylline and salbutamol is used in the treatment of obstructive lung diseases. Side effects (including arrhythmias) of the individual bronchodilator drugs were described, those of combined treatment are almost unknown. We aimed to study the arrhythmogenic potential of combined aminophylline and salbutamol in vitro. Methods: We used the established model of atomic force microscopy (AFM) coupled with cardiac organoids from human pluripotent stem cells (hPSC-CMs). We focused on the chronotropic, inotropic, and arrhythmogenic effects of Salbutamol and Aminophylline alone and combined. Results: Salbutamol and Aminophylline had a synergistic chronotropic and inotropic effects compared to the effects of their separate application. Salbutamol reduced the arrhythmogenic effect of aminophylline, most likely mediated by endothelial nitric oxide synthase activated by beta-2 adrenergic receptors. Findings were replicated and confirmed using hPSC-CM derived from 2 cell lines (CCTL14 and CCTL12). Conclusions: Data suggest that salbutamol as an add-on therapy may not only deliver a bronchodilator effect but also increase the cardiovascular safety of aminophylline, as salbutamol reduces its arrhythmogenic potential. Acknowledgement CarDia (EXCELES, No. LX22NPO5104) EU Next Generation and by the EC Horizon Europe MUQUABIS GA no. 101070546. and MUNI/A/1624/2023 MEYS CR

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů